Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Stifel Financial Corp


Share on StockTwits

Stifel Financial Corp raised its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 2.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,205 shares of the company’s stock after purchasing an additional 180 shares during the quarter. Stifel Financial Corp’s holdings in Kodiak Sciences were worth $1,058,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of KOD. Marshall Wace LLP acquired a new position in Kodiak Sciences in the first quarter valued at $258,000. Marshall Wace North America L.P. acquired a new position in Kodiak Sciences in the first quarter valued at $73,000. JPMorgan Chase & Co. increased its stake in Kodiak Sciences by 13.2% in the third quarter. JPMorgan Chase & Co. now owns 15,275 shares of the company’s stock valued at $906,000 after purchasing an additional 1,779 shares during the period. Great West Life Assurance Co. Can increased its stake in Kodiak Sciences by 44,612.3% in the third quarter. Great West Life Assurance Co. Can now owns 586,178 shares of the company’s stock valued at $383,000 after purchasing an additional 584,867 shares during the period. Finally, UBS Asset Management Americas Inc. increased its stake in Kodiak Sciences by 1.0% in the third quarter. UBS Asset Management Americas Inc. now owns 25,766 shares of the company’s stock valued at $1,526,000 after purchasing an additional 250 shares during the period. Institutional investors own 82.29% of the company’s stock.

In other Kodiak Sciences news, insider Jason Ehrlich sold 6,950 shares of the company’s stock in a transaction dated Monday, March 22nd. The shares were sold at an average price of $131.50, for a total value of $913,925.00. Following the sale, the insider now owns 69,793 shares of the company’s stock, valued at $9,177,779.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 39.30% of the stock is owned by corporate insiders.

A number of research firms have commented on KOD. Berenberg Bank initiated coverage on shares of Kodiak Sciences in a research note on Thursday, December 17th. They issued a “buy” rating and a $156.00 price objective on the stock. Evercore ISI initiated coverage on shares of Kodiak Sciences in a report on Wednesday, March 17th. They issued an “outperform” rating on the stock. Barclays reaffirmed an “underweight” rating and issued a $90.00 target price (up previously from $52.00) on shares of Kodiak Sciences in a report on Monday, March 8th. Smith Barney Citigroup initiated coverage on shares of Kodiak Sciences in a report on Friday, December 11th. They issued a “neutral” rating and a $134.00 target price on the stock. Finally, BMO Capital Markets lowered their target price on shares of Kodiak Sciences from $148.00 to $138.00 and set a “market perform” rating on the stock in a report on Tuesday, March 2nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $131.83.

KOD stock opened at $107.46 on Thursday. The company has a market cap of $5.50 billion, a P/E ratio of -46.32 and a beta of 1.42. Kodiak Sciences Inc. has a 52 week low of $42.02 and a 52 week high of $171.21. The company’s 50-day moving average price is $123.42 and its 200 day moving average price is $135.18.

Kodiak Sciences (NASDAQ:KOD) last released its quarterly earnings data on Sunday, February 28th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.17). As a group, analysts predict that Kodiak Sciences Inc. will post -2.8 earnings per share for the current year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Further Reading: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD).

Institutional Ownership by Quarter for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.